Safely Reducing Patient Hospital Stay After CAR T-Cell Therapy: Remote Patient Monitoring With Morie Gertz, MD

While chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with hematologic malignancies, challenges remain in the management of short-term toxicities, most notably cytokine release syndrome and neurologic symptoms. In nearly all cases to date, optimal management has only been achieved through inpatient admission for frequent monitoring; however, an onsite hospital stay can create a significant burden for the patient. As part of a study recent...

Continue reading

Axicabtagene Ciloleucel and Increasing Accessibility to CAR T-Cell Therapy With Frederick Locke, MD

While the current standard of care for relapsed/refractory large B-cell lymphoma is high-dose therapy with autologous stem cell rescue, many patients do not respond to or cannot tolerate high-dose therapy. As a result, outcomes for second-line treatment remain poor. At the recent American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, Dr. Frederick Locke of Moffitt Cancer Center presented the primary results of ZUMA-7, a phase 3 clinical trial investigating...

Continue reading

Considering CAR T-Cell Therapy Survivorship Care With Sherry Adkins, ANP-C

At the recent 47th Oncology Nursing Society (ONS) Congress in Anaheim, California, Sherry Adkins, MSN, ANP-C, Advanced Practice Provider Supervisor at MD Anderson Cancer Center, gave a presentation entitled CAR T-Cell Therapy: Care and Considerations Beyond Day 28. She highlighted the fact that although the most common acute toxicities associated with chimeric antigen receptor (CAR) T-cell therapy, including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndro...

Continue reading

Oncology Nursing Month With Maria Badillo and Sherry Adkins: Nursing Considerations for CAR T-Cell Therapy

In honor of Oncology Nursing Month in May, Oncology Data Advisor is celebrating the stories of these essential members of the cancer care team. For this interview, editorial board member Maria Badillo, MSN, RN, OCN®, CCRP, speaks with Sherry Adkins, MSN, ANP-C, Advanced Practice Provider Supervisor at MD Anderson Cancer Center, about her groundbreaking research in the development of chimeric antigen (CAR) T-cell therapies and the critical role that oncology nurses play in caring for patients receiving this novel therapeutic strategy.  

Continue reading

Oncology Nursing Month With Maria Badillo and Sherry Adkins: Nursing Considerations for CAR T-Cell Therapy

Oncology Data Advisor™ · Nursing Considerations for CAR T-Cell Therapy With Maria Badillo and Sherry Adkins In honor of Oncology Nursing Month in May, Oncology Data Advisor is celebrating the stories of these essential members of the cancer care team. For this interview, editorial board member Maria Badillo, MSN, RN, OCN®, CCRP, speaks with Sherry Adkins, MSN, ANP-C, Advanced Practice Provider Supervisor at MD Anderson Cancer Center, about her groundbreaking research in the developm...

Continue reading

Interpreting the CAR T Results of Tisagenlecleucel for Relapsed/Refractory Non-Hodgkin Lymphoma: Michael R. Bishop, MD

Michael Bishop, MD.

In the phase 3 BELINDA trial, a team of researchers led by Dr. Michael Bishop, Director of Hematopoietic Stem Cell Transplantation at the University of Chicago Medicine, investigated tisagenlecleucel (tisa-cel), a chimeric antigen receptor (CAR) T-cell therapy, as second-line treatment for patients with relapsed/refractory aggressive non-Hodgkin lymphoma. The investigators found that tisa-cel did not improve event-free survival compared with the standard of care, which consisted of platinum-based chemotherapy followed by autologous stem cell transplant in responders. Dr. Bishop recently presented the results of the trial at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia. In this interview with Oncology Data Advisor, he explains how these results should be interpreted and their significance for the future of CAR T-cell therapy.  

Continue reading

FDA Approves Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

The FDA has approved ciltacabtagene autoleucel (CarvyktiTM, Janssen Biotech) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least four prior lines of treatment, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. "Ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy with 2 B-cell maturation antigen (BCMA)–targeting single-domain antibodies, demonstrated early, dee...

Continue reading

Brexucabtagene Autoleucel Approved: Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

The FDA has approved brexucabtagene autoleucel (TecartusTM, Kite Pharma), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, for patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "Despite treatment with novel therapies and allogeneic stem cell transplant consolidation, outcomes in adult patients with relapsed or refractory B-cell precursor ALL remain poor, underlining the need for more effective therapies," wrote Bijal D. Shah, MD, Ass...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.